BI 690517
DrugBI 690517
Other names: Vicadrostat
NCT Number: NCT05731908
The main objective of this trial is to assess the effect of mild and moderate hepatic impairment (Child-Pugh classification A and B) on the pharmacokinetics, safety, and tolerability of BI 690517 in comparison with a control group with normal hepatic function.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 1
Omega Research Orlando, LLC, Orlando, Florida, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Inclusion criteria
applying only to participants with impaired hepatic function:
Inclusion criteria
applying only to healthy participants with normal hepatic function:
Exclusion criteria
BI 690517
Other names: Vicadrostat
Time frame: Up to 4 days
Time frame: Up to 4 days
Time frame: Up to 4 days
Boehringer Ingelheim
Industry
Pharmacokinetics, Safety, and Tolerability of BI 690517 in Subjects With Mild and Moderate Liver Impairment (Child-Pugh Classification A and B) as Compared to Healthy Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06692322
Digestive System Diseases, Healthy
San Antonio, Texas, United States
View Trial DetailsNCT05296733
Body Weight, Digestive System Diseases
Chandler, Arizona, United States
View Trial DetailsNCT02171832
Digestive System Diseases, Healthy
View Trial DetailsNCT01298063
Digestive System Diseases, Healthy
Kiel, Germany
View Trial Details